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Introduction 
These EANO-ESMO joint recommendations for the diagnosis and treatment of 
leptomeningeal metastasis (LM) from solid cancers represent the first European 
guideline initiative on this topic. LM is defined as the spread of tumour cells within the 
leptomeninges and the subarachnoid space, is synonymous with “neoplastic 
meningitis” and can be further denoted by primary tumour as leptomeningeal 
carcinomatosis, gliomatosis or lymphomatosis. The recommendations address LM 
from solid tumours, but neither LM from primary brain tumours nor LM from 
lymphoma or leukaemia. They cover prevention, diagnosis, therapy and follow-up, 
but not differential diagnosis, adverse effects of therapeutic measures or supportive 
or palliative care. We propose diagnostic criteria as well as a neuroimaging- and 
cytopathology-based classification of LM syndromes to derive pragmatic treatment 
algorithms. We also assign levels of certainty to the diagnosis of LM to provide 
guidance when to treat (as opposed to when to intensify diagnostic efforts) and on 
which patients to include in clinical trials. Given the low level of evidence, the 
recommendations are based more on expert opinion and consensus than on 
evidence from informative clinical trials. Still, these EANO-ESMO multidisciplinary 
recommendations shall serve as a valuable source of information for physicians, 
other health care providers, as well as informed patients and relatives.  
 
Epidemiology 
LM may be diagnosed in approximately 10% of patients with metastatic cancer in the 
course of disease [1]. The incidence is probably underestimated because of non-
specific symptoms and signs, lack of sensitivity to diagnostic procedures and limited 
therapeutic options. Breast cancer, lung cancer and melanoma represent the three 
most common causes of LM, but LM may be observed with all malignant tumours. 
LM occurs in the context of progressive systemic disease in approximately 70% of 
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solid cancer patients with LM, in around 20% at the time of first progression after 
initial treatment, but in up to 10% already at the time of diagnosis. In recent large 
cohorts of LM patients, brain metastases were associated with LM in 33%-54% of 
breast cancer, 56%-82% of lung cancer and 87%-96% of melanoma patients [2-20].  
 
Risk factors for the development of LM include opening of the ventricular system 
during BM surgery or resection of cerebellar metastases, especially when using a 
piece-meal resection [21-26]. In a large cohort of patients with brain metastases, the 
incidence of LM was higher in patients treated with surgery followed by stereotactic 
radiosurgery than in patients treated with radiosurgery alone [27].  
Patients with lobular subtype and triple-negative tumours have a relatively higher risk 
of LM than patients with other types of breast cancer [28]. In recent cohorts, primary 
breast tumours causing LM were ductal carcinoma in 51%-78%, lobular carcinoma in 
26%-35%, human epidermal growth factor receptor-2 (HER2)-positive in 10%-29% 
(up to 47% in only one series) and triple negative in 22%-40.5% [2-7, 9-12, 28].  
Lung tumours causing LM were adenocarcinomas in 84%-96% [13-16, 19]. 
Epidermal growth factor receptor (EGFR)-mutant lung cancer may have a central 
nervous system (CNS) tropism [29-31]. Metastatic CNS involvement has also been 
recognised as an emerging complication in patients with anaplastic lymphoma kinase 
(ALK)-positive non-small-cell lung cancer (NSCLC) [32,33]. In a second-line trial for 
ALK disease, approximately 35% of ALK-positive patients had brain metastases at 
the time of study entry [34].  
Only a few large cohorts of melanoma patients with LM have been reported and risk 
factors, including LM risk-associated molecular profiles (e.g. BRAF mutation status), 
have not been identified.  
The role of cerebrospinal magnetic resonance imaging (MRI) in addition to standard 
extracerebral staging during the follow-up of patients at high risk of LM, e.g. with 
triple negative or lobular breast cancer, has not been evaluated. 
 
Recommendations: 
LM should be considered in particular in patients with breast or lung cancer or melanoma 
who present with neurological symptoms or signs [EANO: III, C; ESMO: III, B]. 
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Prognosis 
Median survival is poor and limited to 6-8 weeks without tumour-specific treatment 
whereas survival may be prolonged to a few months with LM-directed treatment, 
including targeted therapy and immunotherapy: 1.75-4.5 months in breast cancer, 3-
6 months in lung cancer, and 1.7-2.5 months in melanoma (cohorts of more than 30 
patients published within the last 10 years) [2-7, 9-20, 28]. Survival rates at one year 
were 16%-24% for breast cancer [5,12], 19% for lung cancer [13,18] and 7% for 
melanoma patients [19]. Performance status at diagnosis of LM is the most important 
prognostic factor, as shown by multivariate analysis. Other frequently reported 
prognostic factors include primary tumour type, cerebrospinal fluid (CSF) protein 
levels, administration of combined modality treatment, systemic treatment or intra-
CSF treatment, and initial clinical or CSF responses to treatment [2-5, 9-11, 35-39]. 
In contrast, an association of whole brain radiotherapy (WBRT) with overall survival 
(OS) has not been consistently reported [13-16, 28]. 
 
Pathogenesis 
The invasion of the leptomeninges by tumour cells may occur by haematogenous 
spread via the arterial or venous circulation, or endoneural, perineural, perivascular 
or lymphatic spread, especially from breast, lung and head and neck cancers. 
Furthermore, there may be a direct invasion from brain or spinal parenchymal 
metastases in contact with the CSF, the choroid plexus and from subependymal 
metastases [40-42]. Iatrogenic spread may occur after neurosurgical interventions, 
notably when lesioning the ventricles [22]. De novo tumours originating in the 
leptomeninges with melanoma histology are also observed, but represent a distinct 
disease entity [43]. Once seeded in the meninges, tumour cells may disseminate 
along the meningeal and ependymal surfaces or with the CSF flow, with a 
predilection of colonising regions of slow CSF flow and gravity-dependent locations, 
e.g. posterior fossa, basilar cisterns and lumbar cistern [40]. Molecular factors 
facilitating seeding of the leptomeninges by tumour cells have not been identified. 
 
Clinical presentation 
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Symptoms and signs are related to the specific CNS areas involved by LM and thus 
are typically multifocal. The most frequent manifestations at presentation [2, 3, 5, 6, 
7, 11, 13, 15, 18, 19, 20, 44] are: 
• headache  
• nausea and vomiting 
• mental changes 
• gait difficulties 
• cranial nerve palsies, e.g. with diplopia or visual disturbance (cranial nerve VI, 
III, IV, II) and hearing loss (cranial nerve VIII) 
• radicular signs including weakness, voiding and cauda equina problems 
• focal or irradiating (radicular) neck and back pain.  
Some of these symptoms and signs are in part or largely related to increased 
intracranial pressure due to CSF circulation disturbances and can be rapidly 
alleviated by lowering intracranial pressure through CSF drainage. Patients may also 
present with subtle isolated symptoms and signs. Bladder, sexual and bowel 
dysfunction are possibly underreported and should be explored at presentation and 
during the course of the disease. To ensure appropriate clinical management 
strategies, symptoms or signs due to parenchymal metastases, extracranial disease, 
side effects of treatments or non-cancer comorbidities should be distinguished from 
LM-related neurological symptoms and signs. A detailed neurological examination is 
required and a standard evaluation form should be used for the clinical evaluation of 
patients at diagnosis and during follow-up [1]. The Neurologic Assessment in Neuro-
Oncology (NANO) criteria used to assess neurological function in brain tumour 
patients [45] are unlikely to be useful in LM patients because they do not address the 
multi-level involvement of the CNS typically seen in LM. 
 
Recommendations: 
- Typical clinical signs of LM such as headache, nausea and vomiting, mental 
changes, gait difficulties, cranial nerve palsies with diplopia, visual disturbances, 
hearing loss, sensorimotor deficits of extremities and cauda equine syndrome, 
radicular, neck and back pain, notably in a patient with cancer, should alert clinicians 
to consider LM [EANO: IV, n.a; ESMO: V, n.a]. 
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- A detailed neurological examination using a standard evaluation form, e.g. as 
proposed by the Leptomeningeal Assessment in Neuro-Oncology (LANO) group, 
should be carried out at diagnosis [EANO: IV, n.a; ESMO: V, n.a]. 
 
Diagnostic procedures 
Neuroimaging 
Cerebrospinal MRI without and with contrast enhancement using at least 1.5 T field 
strength is the ‘gold standard’ for the comprehensive neuroradiological assessment 
of patients with suspected LM (Table 1) [46]. Characteristic MRI imaging findings 
include sulcal enhancement or obliteration, linear ependymal enhancement, cranial 
nerve root enhancement and leptomeningeal enhancing nodules, notably of the 
cauda equina. Prospective systematic studies addressing sensitivity and specificity of 
MRI in distinguishing LM from other diseases with a similar MRI pattern have not 
been conducted. Sensitivity and specificity of cerebrospinal MRI remain difficult to 
appreciate due to a limited number of publications in patients with a suspicion of LM 
and improvement of technique over time, but have been estimated in the range of 
66%-98% and 77%-97.5%, respectively [47-50]. In recently reported cohorts, 68%-
97% of patients with a diagnosis of LM based on presence of tumour cells in the CSF 
or on typical clinical and MRI findings had radiological evidence of LM on 
cerebrospinal MRI, indicating that the diagnosis of LM is infrequently made in 
patients with a normal MRI [2-5, 7, 9-11, 14, 16-20, 39, 44]. 
The neuroradiological assessment of LM is challenging. Contrast enhancement can 
be complex in geometry and small in volume [1]. Several technical issues, such as 
slice positioning and thickness, time interval between contrast injection and image 
acquisition influence the sensitivity and specificity of neuroimaging. Contrast-
enhanced T1-weighted and fluid-attenuated inversion recovery (FLAIR) sequences 
are probably the most sensitive for the detection of LM [51,52]. Gadolinium should be 
injected 10 min before data acquisition at a dose of 0.1 mmol/kg. The slice thickness 
should be ≤1 mm. As recommended by the LANO group, nodules should be defined 
as ≥ 5x10 mm in orthogonal diameters [1] and should be distinguished from linear 
contrast enhancement. Since meningeal contrast enhancement may also be 
observed after lumbar puncture or ventricular shunt placement, cerebrospinal MRI 
should be obtained prior to such procedures whenever feasible. Communicating 
hydrocephalus is observed in 11%-17% of patients [9, 16]. Cerebrospinal MRI also 
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detects brain metastases, epidural spinal cord compression and intramedullary spinal 
cord metastases. Cranial computed tomography (CT) should be limited to patients 
with contraindications for MRI and mainly helps to identify nodular disease. 18F-
fluorodeoxyglucose positron emission tomography-computed tomography (FDG-
PET-CT) is rarely useful for the diagnosis or follow-up of patients with LM [53]. CSF 
flow studies using intra-CSF application of tracers, such as 111Indium-diethylene 
triamine pentaacetic acid (DTPA) or 99Technetium macro-aggregated albumin, have 
been recommended for patients considered candidates for intra-CSF 
pharmacotherapy, since obstruction to CSF flow may impede coverage of the target 
volume of drug distribution [1]. CSF flow abnormalities have been observed in 61%-
70% of patients in small cohorts of non-selected patients with LM [54,55]. Blocks can 
be partial or complete and can occur at the base of the brain, in the spinal 
subarachnoidal space and over the cerebral convexities.  
 
Recommendations: 
- The diagnostic work-up should include cerebrospinal MRI. Brain MRI should include 
axial T1-weighted, axial FLAIR, axial diffusion, axial T2, post-gadolinium 3D T1 and 
post-gadolinium 3D FLAIR sequences. Spinal MRI should include post-gadolinium 
sagittal T1 sequences. Spine sagittal T1W sequences without contrast and sagittal 
fat suppression T2-weighted sequences, combined with axial T1W images with 
contrast of regions of interest, may also be considered [EANO: III,C; ESMO: II,B]. 
- CSF flow studies should be considered for patients in whom CSF flow obstruction 
may be present, e.g. hydrocephalus, large nodules potentially reducing the CSF 
circulation on MRI, unexpected toxicity of intra-CSF treatment, and who are 
candidates for intra-CSF pharmacotherapy [EANO: IV,n.a.; ESMO: IV,C]. 
 
CSF analysis 
Non-diagnostic pathological findings upon routine CSF analysis are observed in more 
than 90% of LM patients and include increased opening pressure (> 200 mm H2O) in 
21%-42% [16,44], increased leukocyte counts (> 4/mm3) in 48%-77.5% [2, 10, 16, 
44], elevated protein (> 50 mg/dl) in 56%-91% [2, 3, 10, 16, 44] and decreased 
glucose (<60 mg/dl) in 22%-63% [2, 10, 16, 44]. However, only the identification of 
malignant cells in the CSF or in a leptomeningeal biopsy establishes the diagnosis of 
LM (’gold standard’). The results of CSF cytology studies are commonly qualitative 
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and sensitivity is low, although specificity is high. In recent large cohorts of LM 
patients, CSF cytology was considered positive in 66%-90% [3]. CSF cytology should 
be reported as:  
(1) positive, defined by the presence of malignant cells in the CSF;  
(2) equivocal, corresponding to the detection of “suspicious” or “atypical” cells in the 
CSF; or  
(3) negative, defined as the absence of malignant cells in the CSF.  
A distinction of suspicious and atypical as proposed by the LANO group [1] is difficult 
to use in clinical practice. Staining of neoplastic cells for specific alterations such as 
the HER2 protein in breast cancer or BRAFV600E protein in melanoma by 
immunocytochemistry may be useful in selected equivocal cases. The following 
simple measures may improve the sensitivity of CSF studies: obtaining sufficient 
volumes of CSF (ideally >10 mL, but at least 5 mL), processing  CSF within 30 
minutes after sampling, and avoiding haemorrhagic contamination [1, 56-58]. A 
higher sensitivity was reported with thin-layer preparations (Thinprep) than with 
Cytospin-coupled Wright-Giemsa stains [59]. In patients suspected of having LM, 
CSF analysis should be carried out under optimal conditions. If the first CSF analysis 
is negative, a second lumbar puncture should be carried out under optimised 
conditions as outlined above, potentially increasing the sensitivity to 80%. The yield 
of further CSF assessments remains doubtful. CSF fixation in dedicated tubes as 
established for haematological disorders [60], such as ethylenediaminetetraacetic 
acid (EDTA) CSF sample storage tubes or CellSaveTM preservative tubes, may 
diminish the need for rapid processing of the sample, but reports on the validation of 
this approach for solid tumours are lacking.  
Novel techniques using epithelial cell adhesion molecule (Ep-CAM) antibodies or 
other tumour-specific antibody-covered magnetic nanoparticles to identify circulating 
tumour cells have shown promising results using various adaptations of the device 
initially designed for peripheral blood studies, combined with flow cytometry or 
tumour marker immunofluorescence in situ hybridisation (TM-iFISH). Such 
approaches may improve the sensitivity for tumour cell detection in the CSF but need 
validation in prospective studies [45, 61-67]. Genomic alterations can be detected in 
the CSF by micro-arrays [68], digital or real-time polymerase chain reaction (qPCR) 
and targeted amplicon sequencing, and whole exome sequencing [69-72]. Yet, there 
is still insufficient data to substitute a positive CSF cytology by the detection in the 
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CSF of tumour-specific mutations at DNA level, e.g. BRAFV600E or EGFRT790M. It 
remains unclear whether tumour DNA detection in the CSF compartment always 
reflects the local presence of cells or whether this DNA may be derived from tumour 
cells circulating in the blood or even from distant extracerebral metastases. Future 
studies need to address the question which quantitative cut-off load of tumour DNA in 
CSF truly represents clinically relevant LM. 
Numerous CSF biomarkers of LM have been explored in a tumour-specific manner, 
including β-glucuronidase, lactate dehydrogenase, β2-microglobulin, cancer antigen 
(CA) 15-3, CA 125, CA 19-9, α-foetoprotein (AFP), neuron-specific enolase (NSE), or 
Cyfra 21-1 as direct tumour markers, or molecules thought to be involved in the 
metastatic process, specifically angiogenesis (e.g. vascular endothelial growth factor 
(VEGF), tissue plasminogen activator (tPA), stromal cell-derived factor (SDF)-1), 
migration and invasion (e.g. matrix metalloprotease (MMP)-2 and -9, cathepsins B, C 
and H), or adhesion and inflammation (e.g. C-X-C motif chemokine ligand 8 (CXCL-
8) / interleukin-8, CXCL-10 / interferon-inducible protein-10, and CCL18). The role of 
these CSF biomarkers in clinical practice is limited, except for AFP or β-human 
chorionic gonadotropin (hCG) in patients with germ cell tumours, which are not 
covered by this guideline. 
 
Recommendations: 
- CSF studies with optimised analysis conditions must be carried out as part of the 
diagnostic work-up. One repeat lumbar puncture with optimised analysis conditions 
should be carried out in patients with suspected LM and initial negative or equivocal 
CSF studies [EANO: IV, n.a; ESMO: V,n.a]. 
 
Biopsy 
Rarely, leptomeningeal biopsies may be required to confirm the diagnosis of LM. It 
may be useful when CSF cytology is repeatedly negative, when there is no history of 
cancer or if there are doubts about the cause of the clinical and imaging features and 
if therapeutic interventions are clinically indicated. 
 
Diagnostic criteria for LM 
The diagnosis of LM may be challenging, and several subtypes of syndromes 
collectively referred to as LM can be distinguished based on clinical findings, 
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neuroimaging features and CSF analysis. In every case of suspected LM, it should 
be assessed whether any clinical abnormalities are causally related to LM detected 
by neuroimaging or CSF analysis. In most contemporary clinical trials, LM is 
diagnosed based on the detection of malignant cells in the CSF or on suggestive 
clinical and neuroimaging findings in patients with cancer. We propose to classify LM 
by using two major criteria:  
1) Has the diagnosis been verified cytologically or histologically: yes (type I) or no 
(type II)?  
2) What are the neuroimaging findings: linear leptomeningeal disease (type A), 
nodular leptomeningeal disease (type B), both (type C) or neither nor, e.g. no 
neuroimaging evidence of LM except possibly hydrocephalus (type D)? Type C 
should be assigned if the less prevalent phenotype (A or B) still accounts at least for 
an estimated disease burden of at least 20%. 
Based on these considerations, the likelihood of LM can be assigned “confirmed”, 
“probable”, “possible” or “no evidence for” (Table 2). This classification provides 
guidance when to treat with relative confidence (“confirmed”, “probable”) and when to 
reconsider intensified diagnostic efforts at establishing a firm diagnosis (“possible”, 
“no evidence for”). Patients meeting criteria for “no evidence for” should not receive 
LM-directed tumour-specific treatment. Further, we propose that clinical trials should 
only enrol patients with confirmed or probable LM, and should stratify for this 
certainty level of diagnosis.  
 
Therapeutic strategies 
The aim of treatment of LM is to prolong survival with acceptable quality of life, and to 
prevent or delay neurological deterioration. Several tumour-specific approaches can 
be used in isolation or combination. Recommendations for the treatment modalities 
for LM described below are not supported by data from randomised clinical trials; 
they are based on uncontrolled case series and expert opinion, and current 
management strategies vary widely across Europe [73]. 
 
Pharmacotherapy: general considerations 
Based on the assumption that intravenous (i.v.) anti-tumour agents will distribute in 
the same way as i.v. administered contrast agents, there is a priori no reason to 
believe that systemic pharmacotherapy for contrast-enhancing manifestations of LM 
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should be less efficient than for other systemic manifestations of cancer. Moreover, 
increased CSF protein levels in most LM patients confirm that the blood-CSF barrier 
is commonly disrupted in LM and that there must be, therefore, increased levels of 
systemically administered drugs in the CSF of most patients with LM. However, 
floating tumour cells in the CSF in the setting of little or no blood-CSF barrier 
dysfunction or diffuse leptomeningeal or ependymal spread not yet accompanied by 
blood-brain barrier dysfunction may be poorly covered by systemic pharmacotherapy. 
Importantly, in the absence of blood CSF barrier disturbances, drug distribution into 
the CSF depends mainly on drug transport across the choroid plexus and not across 
the blood brain barrier [74]. No specific prospective trials have been reported on 
systemic treatment of LM, but retrospective series suggest some activity of systemic 
chemotherapy [75-77]. Since there are very limited data on the efficacy of targeted 
agents in LM, it remains uncertain whether these agents improve the prognosis of 
LM. 
As for patients brain metastases [78], the best systemic treatment for LM is 
determined by the primary tumour, its molecular characteristics or the molecular 
characteristics of tumour cells of the CSF when available and prior treatment of the 
underlying malignancy. 
 
Recommendations 
- Systemic pharmacotherapy based on primary tumour and previous treatment 
should be considered for most patients with type B/C LM [EANO: IV, n.a.; ESMO: V, 
n.a]. 
 
LM from breast cancer 
Common treatments administered in breast cancer patients with CNS metastases 
include capecitabine, cyclophosphamide, 5-fluorouracil, methotrexate (MTX), 
vincristine, cisplatin, etoposide, vinorelbine and gemcitabine. No trial has specifically 
evaluated the role of trastuzumab in treating brain metastases; however, a clinical 
benefit has been reported in patients with HER2-positive tumours treated for newly 
diagnosed brain metastases [79, 80]. The efficacy of lapatinib was limited in BM 
patients when used alone [81-83], but promising when combined with capecitabine 
[82-86]. Only very limited data are available on the efficacy of trastuzumab-
emtansine (T-DM1) in treating brain metastases [87-89]. 
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There are hardly any systemic studies of LM treatment in patients with breast cancer 
[90]. A concordance of 94% has been reported between the HER2 status of primary 
tumours and the tumour cells in the CSF [91]. In HER2-positive tumours with LM, 
anti-HER2 treatment in combination with chemotherapy should be considered. More 
data are also needed on the efficacy of bevacizumab in combination with various 
chemotherapies in LM patients [92]. Occasional responses to LM have been reported 
with hormonal agents. However, tumours are often resistant to hormonal therapy at 
the time of LM diagnosis. 
 
LM from lung cancer 
A platinum based-combination (including pemetrexed, gemcitabine or paclitaxel for 
non-squamous and unselected NSCLC respectively) can be chosen for treating brain 
metastases from lung cancer [93, 94]. The addition of bevacizumab to classical 
chemotherapy might be beneficial for the treatment of brain metastases in NSCLC 
[95].  
EGFR mutations are observed in 11% of the Caucasian population with lung cancer  
[96] and predict benefit from first (gefitinib, erlotinib) and second generation (afatinib) 
EGFR tyrosine kinase inhibitors (TKIs) [13, 14, 16, 18, 29, 97-101], as well as the 
third generation inhibitor osimertinib in the case of TKIs resistance [102]. In several 
small cohorts, a preservation of the EFGR status was noted in the CSF relative to the 
primary tumour [18, 70, 72, 98]. Erlotinib may achieve higher CSF concentrations 
than gefitinib [103]. New EGFR TKIs such as osimertinib have shown promising 
results in a phase I trial on LM in patients who had progressed on prior EGFR TKI 
therapy [104]. Combinations of EGFR TKIs with other agents await exploration. 
ALK rearrangements and MET mutations are found in 3%-5% and 4% of NSCLC, 
respectively. Crizotinib, which targets ALK,  reactive oxygen species (ROS) and 
MET, represents the first targeted option for ALK-rearranged NSCLC patients since 
the results of the PROFILE 1014 phase III trial [105]. Ceritinib, alectinib or lorlatinib 
may be used after progression under crizotinib according to expert opinion. 
Accumulating evidence suggests a better CNS penetration of these compounds; 
however, only a few reports on the efficacy of second- or third-generation TKIs on LM 
are available [106]. HER2, MET and BRAF mutations as well as RET- and ROS1 
rearrangement have been rarely reported in lung cancer patients with LM. 
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Appropriate inhibitors could represent therapeutic options once such a target has 
been identified. Only preliminary data are available on the efficacy of anti-
programmed cell death 1 (PD1) agents such as nivolumab [107, 108] or 
pembrolizumab [109] or anti-PD ligand 1 such as atezolizumab [110] in NSCLC 
patients with brain metastases [111]. Data on the efficacy of immunotherapy for brain 
metastases or LM are limited since such patients are commonly excluded from 
clinical trials. 
 
LM from melanoma 
Systemic chemotherapy using classical agents such as temozolomide, dacarbazine 
or fotemustine has only limited efficacy in melanoma patients with brain metastases 
or LM. Ipilimumab, an antibody to anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), 
has shown efficacy in patients with brain metastases [112, 113]. Anti-PD1 antibodies 
such as nivolumab or pembrolizumab have shown activity against extracerebral 
disease. However, only preliminary data are available for brain metastases [111]. 
BRAF mutations are observed in 40%-60% of melanomas and a concordance of 
BRAF status of 100% has been observed between primary tumour and brain 
metastases [114] . Responses have been reported in brain metastases or LM 
patients with BRAF inhibitors such as vemurafenib [115, 116] or dabrafenib [117]. 
Although some emerging approaches have shown promising results in the control of 
extracerebral disease, only limited data are available on the efficacy of MAPK/ERK 
kinase (MEK) inhibitors (trametinib, selumetinib, pimarsertib) or the combination of 
BRAF and MEK inhibitors (dabrafenib + trametinib, vemurafenib + cobimetinib) in 
patients with CNS metastases or, specifically, LM from melanoma [20]. 
 
Other solid tumours 
No specific data are available for the treatment of LM caused by other tumours, and 
treatments should be selected according to the primary tumour and its prior 
treatment. 
 
High-dose systemic chemotherapy 
Cytotoxic CSF concentrations of MTX, cytarabine or thiotriethylenephosphoramide 
(thioTEPA) may be achieved using high-dose systemic administration, and these 
agents induced responses in LM from various solid tumours [76, 118-120]. The major 
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limitations of these approaches are haematological toxicity and their incompatibility 
with other systemic regimens potentially needed for the control of systemic disease. 
 
• Intra-CSF pharmacotherapy 
Although no randomised trial has demonstrated that intra-CSF chemotherapy 
prolongs survival in LM patients, intra-CSF pharmacotherapy is used by the majority 
of physicians treating LM patients across Europe [73]. Due to its limited penetration 
into solid tumour lesions, e.g. up to 1-3 mm [121, 122], intra-CSF pharmacotherapy is 
mainly considered for patients with type A LM and a significant tumour cell load in the 
CSF (Table 2). Furthermore, intra-CSF pharmacotherapy should not be administered 
to patients with symptomatic hydrocephalus who require ventriculoperitoneal shunt 
placement or with a ventricular device without on/off option. 
When intra-CSF chemotherapy is used, the administration may be done via repeated 
lumbar punctures or preferably via a subgaleal reservoir and intraventricular catheter. 
An equivalent or larger volume of CSF should be removed before each intra-CSF 
injection. After lumbar injection, patients should remain in a flat position for one hour 
[123]. 
The conceptual advantages of the ventricular route include the certainty that the drug 
is not delivered into the epidural or subdural space instead of the CSF compartment, 
a more uniform distribution of the agent, more patient comfort and a faster procedure, 
which improves compliance and safety of drug administration. The latter is 
particularly true for patients requiring anticoagulation [124-126]. The safety of 
ventricular devices has been shown in several cohorts of patients using different 
technologies and several devices, but careful handling is required to ensure aseptic 
puncture and drug application to minimise the risk of infectious complications [126-
128]. The best surgical procedure has to be defined by the neurosurgeon in charge 
of the patient. No benefit of ventricular versus lumbar route has been demonstrated; 
however, a longer progression-free survival for MTX was observed in a sub-study of 
a randomised trial using the ventricular route, but without significant difference using 
liposomal cytarabine, presumably due to the different half-lives of these agents [124]. 
New approaches such as ventriculolumbar perfusion are interesting, but require 
further study [129].  
Three agents are commonly used for the intrathecal treatment of LM: MTX, 
cytarabine, including liposomal cytarabine, or thioTEPA. Thus, the compounds 
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routinely used for intra-CSF treatment do not have a key role as single agents for 
systemic treatment of most common cancers causing LM. Different schedules have 
been proposed for these agents, without consensus on optimal dose, frequency of 
administration or optimal duration of treatment (Table 3). No intra-CSF agent has 
shown a significant survival advantage over another [130, 131]. Combined intra-CSF 
agents have not demonstrated superiority over single intra-CSF agents [132], yet, 
longer time to neurological progression was reported in LM patients with liposomal 
cytarabine than in those patients treated with MTX [131]. Toxicities of the various 
intra-CSF agents differed. More mucositis or neurological complications such as 
headache were observed with MTX than with thioTEPA [130]. For MTX and 
liposomal cytarabine, Cancer and Leukemia Group B (CALGB)-expanded Common 
Toxicity Criteria treatment-related grade ≥3 toxicity was similar [131]. In a 
subanalysis, a greater quality-adjusted survival, measured by quality-adjusted time 
without symptoms or toxicity (Q-TWIST), was observed in patients treated with 
liposomal cytarabine than with MTX [133].  
The efficacy and tolerance of intra-CSF trastuzumab in HER2-positive breast cancer 
is under evaluation in two trials (NCT01325207, NCT01373710). A small pooled 
analysis of 17 patients with HER2-positive breast cancer from 13 publications treated 
by intra-CSF trastuzumab reported clinical improvement in 69% of patients, with a 
median OS of 13.5 months [134].  
A critical review of the randomised trials on LM, five of which enrolled patients with 
solid tumours [75, 125, 130-132] (Supplementary Table 1), all assessing the 
response to intra-CSF therapy, revealed a lack of standardisation for the evaluation 
of response and methodological limitations with respect to the type of tumour 
(haematological versus solid), baseline evaluation, response to treatment and 
evaluation of safety, and all experienced long times for accrual [46]. Moreover, all 
were open-label studies. Only cohort studies have been reported in recent years.  
One single trial tried to explore the value of adding intra-ventricular MTX to systemic 
therapy and involved-field radiotherapy (RT), but the trial was prematurely closed 
[75]. A total of 35 breast cancer patients with LM were evaluated based on clinical 
findings only. No differences for clinical response or OS were observed, but more 
treatment-related neurotoxicity, scored according to a local scale, was noted in the 
intra-CSF chemotherapy arm (47% versus 6%). The complication rate in the intra-
CSF chemotherapy arm, with 18% of reservoir revisions, was also high compared 
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with other cohorts (<7.3% of reservoir revision) [126-128]. The role of adding intra-
CSF chemotherapy using liposomal cytarabine to systemic therapy in breast cancer 
patients with LM is re-addressed in an ongoing phase III trial (NCT01645839). 
The optimal duration of intra-CSF treatment has also not been adequately explored. 
Most patients are nowadays treated until progression or for one year, if tolerated. In 
the absence of evidence from appropriate clinical trials, clinical symptoms and MRI 
and CSF findings, as well as tolerance of treatment, guide individual decisions on the 
duration of treatment. Notably, the role of persisting positive CSF cytology alone for 
decision-making regarding the continuation of treatment remains controversial [1].  
 
Recommendations 
- Intra-CSF pharmacotherapy should be considered for most patients with type IA/C 
LM [EANO: IV, n.a.; ESMO: V, n.a]. 
- Intra-CSF chemotherapy should be administered via the ventricular rather than 
lumbar route whenever feasible [EANO: IV, n.a; ESMO: V, n.a]. 
 
Radiotherapy 
No randomised clinical trial to assess the efficacy and tolerance of RT in LM has 
been conducted. Focal RT administered in fractionated regimens such as involved-
field or stereotactic RT or administered in single fractions (radiosurgery) can be used 
to treat nodular disease and symptomatic cerebral or spinal sites. 
In exceptional cases, focal RT can be carried out for cauda equina syndrome or 
cranial nerve palsies after exclusion of other causes even in the absence of 
corresponding MRI findings. The presence of CSF flow interruptions is associated 
with decreased survival [54, 55, 135]. Restoration of CSF flow obstruction can be 
obtained by focal RT in 30% of patients with spinal blocks and in 50% of patients with 
intracranial blocks [136] and has been proposed to reduce the toxicity from, and 
enhance the efficacy of, intra-CSF therapy. 
Typical target volumes for RT in the presence of cranial neuropathies include, by 
expert consensus, the skull base, the interpeduncular cistern and the two first 
cervical vertebrae. Typical target volumes for RT in the presence of a cauda equina 
syndrome include the lumbosacral vertebrae. WBRT may be considered for 
extensive nodular or symptomatic linear LM or co-existing brain metastases. Yet, no 
association of WBRT with survival was observed in retrospective studies of LM 
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patients [13, 14, 15, 18, 28]. Cerebrospinal RT is rarely an option for adult patients 
with LM from solid cancers because of risk of bone marrow toxicity, enteritis and 
mucositis, and the usual co-existence of systemic disease. Concomitant craniospinal 
RT and systemic or intra-CSF treatment should be avoided to prevent severe toxicity, 
notably myelosuppression. Up to 20% of grade 3-4 adverse events have been 
reported in a phase II trial evaluating concomitant intra-CSF MTX plus 
dexamethasone with focal RT for patients with LM from various solid tumours [137]. 
Intra-CSF administration of radioisotopes or radiolabelled monoclonal antibodies 
should be explored in the context of clinical trials.  
 
Recommendations 
- Focal RT should be considered for circumscribed, notably symptomatic lesions  
[EANO: IV, n.a; ESMO: V, n.a]. 
- WBRT can be considered for extensive nodular or symptomatic linear LM [EANO: 
IV, n.a; ESMO: V, n.a]. 
 
Individualised approach to LM 
Diagnosis and management of patients with LM should follow multidisciplinary 
tumour board recommendations throughout the disease course. The therapeutic 
strategy should consider general health and the neurological status of the patient, 
histological and molecular subtype of the primary cancer, extent and available 
therapeutic options for extra-CNS disease, clinical and imaging presentation of LM, 
and presence of concomitant brain metastases. The therapeutic recommendations 
summarised in Figures 1-3 and Table 4 are largely based on retrospective cohort 
data or expert agreements and must be considered as of low level of evidence. 
Randomised clinical trials with adapted methodology and standardised criteria for 
diagnosis and response are needed to better define the role of systemic and intra-
CSF treatments. 
 
Monitoring and follow-up 
No robust data are available and monitoring recommendations today are still based 
on consensus and expert opinion. The LANO group has made efforts to determine 
criteria to evaluate the response to treatment in LM patients [1] (Supplementary 
Table 2). While the proposal by the LANO group remains controversial largely 
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because of its complexity, we concur with the view that response should be 
evaluated according to a complete neurological assessment, a neuroimaging 
evaluation, and standard CSF cytology. CSF parameters other than the detection of 
tumour cells are not considered (Table 5). Symptoms and signs related to 
concomitant brain metastases, extracerebral progression, toxicity induced by 
treatments or concurrent diseases must not be considered for the evaluation of LM 
response. Since most neurological deficits in LM patients are irreversible, the best 
anticipated clinical response is usually achievement of stable disease. A complete 
cerebrospinal MRI is required for the evaluation of response. During follow-up, MRI 
should preferably be repeated using the same scanner or at least a scanner of 
identical field strength (Table 1). Other imaging modalities such as magnetic 
resonance (MR) spectroscopy, MR perfusion or PET have no role so far in the 
assessment of LM during follow-up. The LANO group has proposed a MRI grid for 
the assessment of radiographic response, which needs to be validated. Due to small 
volume and geometric complexity, a quantitative assessment is often not possible, 
and LM lesions may be difficult to measure reliably. Thus, it has been proposed to 
distinguish “measurable” LM disease defined by at least one nodular lesion of more 
than 5x10 mm from “non-measurable” disease which encompasses all other MRI 
abnormalities [1]. Changes in size, but not changes in intensity of contrast 
enhancement, should be considered. Changes in hydrocephalus should be 
considered as part of the response evaluation in clinical practice, but were not 
included in the LANO MRI grid. In clinical trials, concomitant brain or extradural 
spinal metastases are evaluated separately for response. 
CSF cell counts could, in principle, be obtained specifically for tumour, as opposed to 
non-neoplastic cells, but this has remained challenging and would require more 
sophisticated techniques than commonly available. As discussed above, the proposal 
by the LANO group to classify the standard CSF cytology results into four groups of 
negative, atypical, suspicious, and positive appears too complex, but three 
categories of positive, equivocal or negative seem to be more feasible in clinical 
practice (see above). A complete CSF cytological response requires a conversion of 
a previously positive to a negative CSF response maintained for at least 4 weeks. If 
only lumbar CSF was positive and the patient is treated via a ventricular reservoir, 
the CSF response cannot be evaluated unless further lumbar CSF samples are 
obtained. An unequivocal de novo appearance of malignant cells in the CSF after 
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repeated negative CSF cytologies carried out under optimised conditions should be 
considered as progression and does not require a confirmatory analysis. In contrast, 
a change from negative to equivocal is not considered relevant for clinical decision 
making. CSF cytology may remain positive in patients with stable or improved clinical 
or imaging features [138]. The levels of CSF protein, glucose or lactate, or novel 
biomarkers or new methodologies for the identification of tumour cells in the CSF 
have not been integrated into routine response determination at present. 
Clinical, imaging and CSF evaluations should be carried out at baseline and at 
defined time points thereafter to assess the response. Evaluations should be planned 
every two months for the first 6 months and every three months thereafter in stable 
patients, but should be carried out earlier whenever there is suspicion of progression 
based on clinical assessment. 
 
Recommendations 
- A detailed neurological examination using a standard evaluation form should be 
carried out every 2-3 months or at radiological progression or when new neurological 
symptoms or signs are reported [EANO: IV, n.a; ESMO: V, n.a]. 
- Cerebrospinal MRI should be carried out every 2-3 months or at any instance of 
suspected clinical progression [EANO: IV, n.a; ESMO: V, n.a]. 
- CSF studies should be carried out every 2-3 months in patients undergoing intra-
CSF pharmacotherapy [EANO: IV, n.a; ESMO: V, n.a]. 
 
Supportive care 
While this guideline does not aim at comprehensively describing palliative and 
supportive care, a few points deserve consideration. The role of steroids has not 
been specifically studied in LM patients, notwithstanding their role for associated 
brain metastases, chemical meningitis or other systemic complications of cancer. 
Steroids may also alleviate meningeal irritation and radicular pain. When required 
clinically, the lowest dose of steroids should be used for the shortest time possible. 
Seizures should be managed using drugs that do not interact with systemic 
treatments. Primary prophylaxis is not recommended [139, 140]. Ventriculoperitoneal 
shunting may provide durable relief from symptomatic hydrocephalus [141-144]. 
National and institutional guidelines may provide further guidance [145]. 
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Outlook 
Guidelines reflect knowledge and consensus at a given timepoint.  Updates on these 
recommendations will be announced on the website of EANO (www.eano.eu) and 
ESMO (www.esmo.org). 
Randomised trials based on well-defined diagnostic and inclusion criteria, in 
appropriately selected sub-groups of LM patients, enriched for molecular genetic 
signatures where feasible, and with adequate criteria of evaluation are required to 
improve the outcome of LM in a primary cancer-specific manner. Important questions 
to address include the role of intrathecal pharmacotherapy and of novel systemic 
therapies, notably targeted agents and immunotherapy. 
 
Methodology 
References were identified through searches of PubMed with the search terms 
“leptomeningeal metastasis”, “neoplastic meningitis”, “intrathecal”, “intra-CSF”, 
“CNS”, “brain”, “metastasis”, “trial”, “clinical”, “radiotherapy” and “chemotherapy” in 
various combinations from 1 January 1976 to 30 November 2016, because of the 
paucity of data on this topic. Articles were also identified through searches of the 
authors` own files. Only papers in English were reviewed. Data available only in 
Abstract form were only exceptionally included. The final reference list was 
generated by consensus of the authors and based on originality and relevance to the 
broad scope of this guideline. Levels of evidence and grades of recommendation 
were applied using the European Federation of Neurological Societies criteria as 
recommended by EANO (Tables 6 and 7) [146] as well as using an adapted version 
of the Infectious Disease Society of America-United States Public Health Service 
Grading System as recommended by ESMO (Table 8) [147]. Statements without 
grading were considered justified standard clinical practice by the experts. This 
manuscript has been subjected to an anonymous peer review process. 
 
Disclosure 
ELR has received research support from Mundipharma and Amgen. MW has 
received research grants from Acceleron, Actelion, Bayer, Isarna, MSD, Merck EMD, 
Novocure, Piqur and Roche and honoraria for lectures or advisory board participation 
or consulting from Bristol-Myers Squibb, Celldex, Immunocellular Therapeutics, 
 21 
Isarna, Magforce, MSD, Merck EMD, Northwest Biotherapeutics, Novocure, Pfizer, 
Roche, Teva and Tocagen. DB has received research support from BBB 
therapeutics. EA has received advisory board from Roche; travels grant from Roche 
and GlaxoSmithKline; research grant from Roche. MP has received research support 
from Böhringer-Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme and Roche and 
honoraria for lectures, consultation or advisory board participation from Bristol-Myers 
Squibb, Novartis, Gerson Lehrman Group, CMC Contrast, GlaxoSmithKline, 
Mundipharma, Roche and AstraZeneca. The other authors have declared no 
potential conflicts of interest.  
 
 
 
 
 
References 1.  Chamberlain M, Junck L, Brandsma D et al. Leptomeningeal metastases: a 
RANO proposal for response criteria. Neuro-Oncol. 2016. 
doi:10.1093/neuonc/now183. 
2.  Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal 
metastasis--the role of multimodality treatment. J. Neurooncol. 2007; 84(1):57–62. 
3.  Gauthier H, Guilhaume MN, Bidard FC et al. Survival of breast cancer patients 
with meningeal carcinomatosis. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 
2010; 21(11):2183–2187. 
4.  Lee S, Ahn HK, Park YH et al. Leptomeningeal metastases from breast 
cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer 
Res. Treat. 2011; 129(3):809–817. 
5.  de Azevedo CRAS, Cruz MRS, Chinen LTD et al. Meningeal carcinomatosis in 
breast cancer: prognostic factors and outcome. J. Neurooncol. 2011; 104(2):565–
572. 
6.  Lara-Medina F, Crismatt A, Villarreal-Garza C et al. Clinical features and 
prognostic factors in patients with carcinomatous meningitis secondary to breast 
cancer. Breast J. 2012; 18(3):233–241. 
7.  Meattini I, Livi L, Saieva C et al. Prognostic factors and clinical features in 
patients with leptominengeal metastases from breast cancer: a single center 
experience. J. Chemother. Florence Italy 2012; 24(5):279–284. 
8.  Kim H-J, Im S-A, Keam B et al. Clinical outcome of central nervous system 
metastases from breast cancer: differences in survival depending on systemic 
treatment. J. Neurooncol. 2012; 106(2):303–313. 
9.  Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal 
metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis 
Kommentiert [SE-E1]: To Annals 
Ref 45: In Press in Neuro-Oncology.  
Please check if published   
  
Kommentiert [SE-E2]: To Annals Please format the references 
 22 
of factors influencing survival. Med. Oncol. Northwood Lond. Engl. 2013; 30(1):408. 
10.  Yust-Katz S, Garciarena P, Liu D et al. Breast cancer and leptomeningeal 
disease (LMD): hormone receptor status influences time to development of LMD and 
survival from LMD diagnosis. J. Neurooncol. 2013; 114(2):229–235. 
11.  Le Rhun E, Taillibert S, Zairi F et al. A retrospective case series of 103 
consecutive patients with leptomeningeal metastasis and breast cancer. J. 
Neurooncol. 2013; 113(1):83–92. 
12.  Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal 
metastasis: the results of combined treatment and the comparison of methotrexate 
and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin. Breast 
Cancer 2015; 15(1):66–72. 
13.  Morris PG, Reiner AS, Szenberg OR et al. Leptomeningeal metastasis from 
non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J. 
Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2012; 7(2):382–385. 
14.  Park JH, Kim YJ, Lee J-O et al. Clinical outcomes of leptomeningeal 
metastasis in patients with non-small cell lung cancer in the modern chemotherapy 
era. Lung Cancer Amst. Neth. 2012; 76(3):387–392. 
15.  Gwak H-S, Joo J, Kim S et al. Analysis of treatment outcomes of 
intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from 
non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung 
Cancer 2013; 8(5):599–605. 
16.  Lee SJ, Lee J-I, Nam D-H et al. Leptomeningeal carcinomatosis in non-small-
cell lung cancer patients: impact on survival and correlated prognostic factors. J. 
Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2013; 8(2):185–191. 
17.  Riess JW, Nagpal S, Iv M et al. Prolonged survival of patients with non-small-
cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. 
Clin. Lung Cancer 2014; 15(3):202–206. 
18.  Kuiper JL, Hendriks LE, van der Wekken AJ et al. Treatment and survival of 
patients with EGFR-mutated non-small cell lung cancer and leptomeningeal 
metastasis: A retrospective cohort analysis. Lung Cancer Amst. Neth. 2015; 
89(3):255–261. 
19.  Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients 
with leptomeningeal melanomatosis. Neuro-Oncol. 2008; 10(6):1010–1018. 
20.  Geukes Foppen MH, Brandsma D, Blank CU et al. Targeted treatment and 
immunotherapy in leptomeningeal metastases from melanoma. Ann. Oncol. Off. J. 
Eur. Soc. Med. Oncol. 2016; 27(6):1138–1142. 
21.  Roelz R, Reinacher P, Jabbarli R et al. Surgical Ventricular Entry is a Key Risk 
Factor for Leptomeningeal Metastasis of High Grade Gliomas. Sci. Rep. 2015; 
5:17758. 
22.  Ahn JH, Lee SH, Kim S et al. Risk for leptomeningeal seeding after resection 
for brain metastases: implication of tumor location with mode of resection. J. 
Neurosurg. 2012; 116(5):984–993. 
23.  Elliott JP, Keles GE, Waite M et al. Ventricular entry during resection of 
malignant gliomas: effect on intracranial cerebrospinal fluid tumor dissemination. J. 
Neurosurg. 1994; 80(5):834–839. 
24.  Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical 
resection of isolated cerebellar metastasis: a potentially preventable complication. J. 
Neurooncol. 1997; 32(3):215–223. 
25.  van der Ree TC, Dippel DW, Avezaat CJ et al. Leptomeningeal metastasis 
after surgical resection of brain metastases. J. Neurol. Neurosurg. Psychiatry 1999; 
66(2):225–227. 
 23 
26.  Suki D, Hatiboglu MA, Patel AJ et al. Comparative risk of leptomeningeal 
dissemination of cancer after surgery or stereotactic radiosurgery for a single 
supratentorial solid tumor metastasis. Neurosurgery 2009; 64(4):664-674-676. 
27.  Johnson MD, Avkshtol V, Baschnagel AM et al. Surgical Resection of Brain 
Metastases and the Risk of Leptomeningeal Recurrence in Patients Treated With 
Stereotactic Radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 2016; 94(3):537–543. 
28.  Abouharb S, Ensor J, Loghin ME et al. Leptomeningeal disease and breast 
cancer: the importance of tumor subtype. Breast Cancer Res. Treat. 2014; 
146(3):477–486. 
29.  Liao B-C, Lee J-H, Lin C-C et al. Epidermal Growth Factor Receptor Tyrosine 
Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal 
Carcinomatosis. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2015; 
10(12):1754–1761. 
30.  Matsumoto S, Takahashi K, Iwakawa R et al. Frequent EGFR mutations in 
brain metastases of lung adenocarcinoma. Int. J. Cancer 2006; 119(6):1491–1494. 
31.  Iuchi T, Shingyoji M, Itakura M et al. Frequency of brain metastases in non-
small-cell lung cancer, and their association with epidermal growth factor receptor 
mutations. Int. J. Clin. Oncol. 2015; 20(4):674–679. 
32.  Gainor JF, Ou S-HI, Logan J et al. The central nervous system as a sanctuary 
site in ALK-positive non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. 
Assoc. Study Lung Cancer 2013; 8(12):1570–1573. 
33.  Lee D-W, Lee K-H, Kim JW, Keam B. Molecular Targeted Therapies for the 
Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future 
Directions. Int. J. Mol. Sci. 2016. doi:10.3390/ijms17071074. 
34.  Shaw AT, Kim D-W, Nakagawa K et al. Crizotinib versus chemotherapy in 
advanced ALK-positive lung cancer. N. Engl. J. Med. 2013; 368(25):2385–2394. 
35.  Clarke JL, Perez HR, Jacks LM et al. Leptomeningeal metastases in the MRI 
era. Neurology 2010; 74(18):1449–1454. 
36.  Oechsle K, Lange-Brock V, Kruell A et al. Prognostic factors and treatment 
options in patients with leptomeningeal metastases of different primary tumors: a 
retrospective analysis. J. Cancer Res. Clin. Oncol. 2010; 136(11):1729–1735. 
37.  Herrlinger U, Wiendl H, Renninger M et al. Vascular endothelial growth factor 
(VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br. J. Cancer 
2004; 91(2):219–224. 
38.  Clatot F, Philippin-Lauridant G, Ouvrier M-J et al. Clinical improvement and 
survival in breast cancer leptomeningeal metastasis correlate with the cytologic 
response to intrathecal chemotherapy. J. Neurooncol. 2009; 95(3):421–426. 
39.  Hyun J-W, Jeong IH, Joung A et al. Leptomeningeal metastasis: Clinical 
experience of 519 cases. Eur. J. Cancer Oxf. Engl. 1990 2016; 56:107–114. 
40.  Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by 
tumour--a clinical and pathological study of 63 cases. Postgrad. Med. J. 1980; 
56(653):149–158. 
41.  Gonzalez-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 
1976; 37(6):2906–2911. 
42.  Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-
arachnoid? Cancer 1983; 51(1):154–160. 
43.  Küsters-Vandevelde HVN, Küsters B, van Engen-van Grunsven ACH et al. 
Primary melanocytic tumors of the central nervous system: a review with focus on 
molecular aspects. Brain Pathol. Zurich Switz. 2015; 25(2):209–226. 
44.  Kwon J, Chie EK, Kim K et al. Impact of multimodality approach for patients 
with leptomeningeal metastases from solid tumors. J. Korean Med. Sci. 2014; 
 24 
29(8):1094–1101. 
45.  Nayak L, DeAngelis LM, Brandes A et al. The Neurologic Assessment in 
Neuro-Oncology (NANO) scale: A tool to assess neurologic function for integration in 
the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro-Oncology. 
2017 (In Press). 
46.  Chamberlain M, Soffietti R, Raizer J et al. Leptomeningeal metastasis: a 
Response Assessment in Neuro-Oncology critical review of endpoints and response 
criteria of published randomized clinical trials. Neuro-Oncol. 2014; 16(9):1176–1185. 
47.  Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid 
cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 1995; 38(1):51–
57. 
48.  Singh SK, Agris JM, Leeds NE, Ginsberg LE. Intracranial leptomeningeal 
metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging. 
Radiology 2000; 217(1):50–53. 
49.  Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of 
magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal 
metastasis. J. Neurol. 1999; 246(9):810–814. 
50.  Zeiser R, Burger JA, Bley TA et al. Clinical follow-up indicates differential 
accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal 
fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br. J. 
Haematol. 2004; 124(6):762–768. 
51.  Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal 
metastases: comparison of three sequences. AJNR Am. J. Neuroradiol. 2002; 
23(5):817–821. 
52.  Mahendru G, Chong V. Meninges in cancer imaging. Cancer Imaging Off. 
Publ. Int. Cancer Imaging Soc. 2009; 9 Spec No A:S14-21. 
53.  Lombardi G, Zustovich F, Farina P et al. Neoplastic meningitis from solid 
tumors: new diagnostic and therapeutic approaches. The Oncologist 2011; 
16(8):1175–1188. 
54.  Grossman SA, Trump DL, Chen DC et al. Cerebrospinal fluid flow 
abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-
DTPA ventriculography. Am. J. Med. 1982; 73(5):641–647. 
55.  Glantz MJ, Hall WA, Cole BF et al. Diagnosis, management, and survival of 
patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 
1995; 75(12):2919–2931. 
56.  Glantz MJ, Cole BF, Glantz LK et al. Cerebrospinal fluid cytology in patients 
with cancer: minimizing false-negative results. Cancer 1998; 82(4):733–739. 
57.  Rogers LR, Duchesneau PM, Nunez C et al. Comparison of cisternal and 
lumbar CSF examination in leptomeningeal metastasis. Neurology 1992; 42(6):1239–
1241. 
58.  Dux R, Kindler-Röhrborn A, Annas M et al. A standardized protocol for flow 
cytometric analysis of cells isolated from cerebrospinal fluid. J. Neurol. Sci. 1994; 
121(1):74–78. 
59.  Pan Z, Yang G, Wang Y et al. Thinprep plus Papanicolaou stain method is 
more sensitive than cytospin-coupled Wright Giems stain method in cerebrospinal 
fluid cytology for diagnosis of leptomeningeal metastasis from solid tumors. PloS One 
2015; 10(4):e0122016. 
60.  Quijano S, López A, Manuel Sancho J et al. Identification of leptomeningeal 
disease in aggressive B-cell non-Hodgkin’s lymphoma: improved sensitivity of flow 
cytometry. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009; 27(9):1462–1469. 
61.  Patel AS, Allen JE, Dicker DT et al. Identification and enumeration of 
 25 
circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central 
nervous system metastases. Oncotarget 2011; 2(10):752–760. 
62.  Le Rhun E, Massin F, Tu Q et al. Development of a new method for 
identification and quantification in cerebrospinal fluid of malignant cells from breast 
carcinoma leptomeningeal metastasis. BMC Clin. Pathol. 2012; 12:21. 
63.  Lee JS, Melisko ME, Magbanua MJM et al. Detection of cerebrospinal fluid 
tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. 
Breast Cancer Res. Treat. 2015; 154(2):339–349. 
64.  Milojkovic Kerklaan B, Pluim D, Bol M et al. EpCAM-based flow cytometry in 
cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal 
metastases from epithelial tumors. Neuro-Oncol. 2016; 18(6):855–862. 
65.  Ma C, Lv Y, Jiang R et al. Novel method for the detection and quantification of 
malignant cells in the CSF of patients with leptomeningeal metastasis of lung cancer. 
Oncol. Lett. 2016; 11(1):619–623. 
66.  Subirá D, Simó M, Illán J et al. Diagnostic and prognostic significance of flow 
cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin. 
Exp. Metastasis 2015; 32(4):383–391. 
67.  Tu Q, Wu X, Le Rhun E et al. CellSearch technology applied to the detection 
and quantification of tumor cells in CSF of patients with lung cancer leptomeningeal 
metastasis. Lung Cancer Amst. Neth. 2015; 90(2):352–357. 
68.  Magbanua MJM, Roy R, Sosa EV et al. Genome-wide copy number analysis 
of cerebrospinal fluid tumor cells and their corresponding archival primary tumors. 
Genomics Data 2014; 2:60–62. 
69.  Li Y, Pan W, Connolly ID et al. Tumor DNA in cerebral spinal fluid reflects 
clinical course in a patient with melanoma leptomeningeal brain metastases. J. 
Neurooncol. 2016; 128(1):93–100. 
70.  Sasaki S, Yoshioka Y, Ko R et al. Diagnostic significance of cerebrospinal fluid 
EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer 
patients harboring an active EGFR mutation following gefitinib therapy failure. Respir. 
Investig. 2016; 54(1):14–19. 
71.  Shingyoji M, Kageyama H, Sakaida T et al. Detection of epithelial growth 
factor receptor mutations in cerebrospinal fluid from patients with lung 
adenocarcinoma suspected of neoplastic meningitis. J. Thorac. Oncol. Off. Publ. Int. 
Assoc. Study Lung Cancer 2011; 6(7):1215–1220. 
72.  Yang H, Cai L, Zhang Y et al. Sensitive detection of EGFR mutations in 
cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J. Mol. 
Diagn. JMD 2014; 16(5):558–563. 
73.  Le Rhun E, Rudà R, Riccardo R, Weller M. Bmet-18. Diagnosis and Treatment 
Patterns for Patients with Leptomeningeal Metastasis from Solid Tumors Across 
Europe. Neuro- Oncol. 2016; 18(suppl 6):vi30-vi30.  
74.  Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin. 
Drug Deliv. 2016; 13(7):963–975. 
75.  Boogerd W, van den Bent MJ, Koehler PJ et al. The relevance of 
intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a 
randomised study. Eur. J. Cancer Oxf. Engl. 1990 2004; 40(18):2726–2733. 
76.  Glantz MJ, Cole BF, Recht L et al. High-dose intravenous methotrexate for 
patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy 
necessary? J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1998; 16(4):1561–1567. 
77.  Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid 
tumors: a comparison of two prospective series treated with and without intra-
cerebrospinal fluid chemotherapy. Cancer 1998; 82(9):1756–1763. 
 26 
78.  Soffietti R, Abacioglu U, Baumert B et al. Diagnosis and treatment of brain 
metastases from solid tumors: guidelines from the European Association of Neuro-
Oncology (EANO). Neuro-Oncol. 2017; 19(2):162–174. 
79.  Church DN, Modgil R, Guglani S et al. Extended survival in women with brain 
metastases from HER2 overexpressing breast cancer. Am. J. Clin. Oncol. 2008; 
31(3):250–254. 
80.  Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in 
patients with HER2-positive metastatic breast cancer: incidence, treatment, and 
survival in patients from registHER. Clin. Cancer Res. Off. J. Am. Assoc. Cancer 
Res. 2011; 17(14):4834–4843. 
81.  Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases 
in patients with human epidermal growth factor receptor 2-positive breast cancer. J. 
Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2008; 26(12):1993–1999. 
82.  Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in 
patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 
Off. J. Am. Assoc. Cancer Res. 2009; 15(4):1452–1459. 
83.  Toi M, Iwata H, Fujiwara Y et al. Lapatinib monotherapy in patients with 
relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker 
results from Japanese patients phase II studies. Br. J. Cancer 2009; 101(10):1676–
1682. 
84.  Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in 
patients with previously untreated brain metastases from HER2-positive metastatic 
breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 
14(1):64–71. 
85.  Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain 
metastases from HER2-positive breast cancer treated with lapatinib and 
capecitabine. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2011; 22(3):625–630. 
86.  Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic 
breast cancer with lapatinib and capecitabine in the lapatinib expanded access 
programme, including efficacy in brain metastases--the UK experience. Br. J. Cancer 
2010; 102(6):995–1002. 
87.  Bartsch R, Berghoff AS, Vogl U et al. Activity of T-DM1 in Her2-positive breast 
cancer brain metastases. Clin. Exp. Metastasis 2015; 32(7):729–737. 
88.  Keith KC, Lee Y, Ewend MG et al. ACTIVITY OF TRASTUZUMAB-
EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN 
METASTASES: A CASE SERIES. Cancer Treat. Commun. 2016; 7:43–46. 
89.  Jacot W, Pons E, Frenel J-S et al. Efficacy and safety of trastuzumab 
emtansine (T-DM1) in patients with HER2-positive breast cancer with brain 
metastases. Breast Cancer Res. Treat. 2016; 157(2):307–318. 
90.  Dudani S, Mazzarello S, Hilton J et al. Optimal Management of 
Leptomeningeal Carcinomatosis in Breast Cancer Patients-A Systematic Review. 
Clin. Breast Cancer 2016; 16(6):456–470. 
91.  Park IH, Kwon Y, Ro JY et al. Concordant HER2 status between metastatic 
breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res. 
Treat. 2010; 123(1):125–128. 
92.  Wu P-F, Lin C-H, Kuo C-H et al. A pilot study of bevacizumab combined with 
etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. 
BMC Cancer 2015; 15:299. 
93.  Li M, Zhang Q, Fu P et al. Pemetrexed plus platinum as the first-line treatment 
option for advanced non-small cell lung cancer: a meta-analysis of randomized 
controlled trials. PloS One 2012; 7(5):e37229. 
 27 
94.  Zimmermann S, Dziadziuszko R, Peters S. Indications and limitations of 
chemotherapy and targeted agents in non-small cell lung cancer brain metastases. 
Cancer Treat. Rev. 2014; 40(6):716–722. 
95.  Besse B, Le Moulec S, Mazières J et al. Bevacizumab in Patients with 
Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain 
Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin. Cancer Res. Off. J. 
Am. Assoc. Cancer Res. 2015; 21(8):1896–1903. 
96.  Barlesi F, Mazieres J, Merlio J-P et al. Routine molecular profiling of patients 
with advanced non-small-cell lung cancer: results of a 1-year nationwide programme 
of the French Cooperative Thoracic Intergroup (IFCT). Lancet Lond. Engl. 2016; 
387(10026):1415–1426. 
97.  Umemura S, Tsubouchi K, Yoshioka H et al. Clinical outcome in patients with 
leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer 
Study Group. Lung Cancer Amst. Neth. 2012; 77(1):134–139. 
98.  Kawamura T, Hata A, Takeshita J et al. High-dose erlotinib for refractory 
leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer 
Chemother. Pharmacol. 2015; 75(6):1261–1266. 
99.  Jackman DM, Cioffredi LA, Jacobs L et al. A phase I trial of high dose gefitinib 
for patients with leptomeningeal metastases from non-small cell lung cancer. 
Oncotarget 2015; 6(6):4527–4536. 
100.  Tetsumoto S, Osa A, Kijima T et al. Two cases of leptomeningeal metastases 
from lung adenocarcinoma which progressed during gefitinib therapy but responded 
to erlotinib. Int. J. Clin. Oncol. 2012; 17(2):155–159. 
101.  Hoffknecht P, Tufman A, Wehler T et al. Efficacy of the irreversible ErbB family 
blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor 
(TKI)-pretreated non-small-cell lung cancer patients with brain metastases or 
leptomeningeal disease. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 
2015; 10(1):156–163. 
102.  Mok TS, Wu Y-L, Ahn M-J et al. Osimertinib or Platinum-Pemetrexed in EGFR 
T790M-Positive Lung Cancer. N. Engl. J. Med. 2017; 376(7):629–640. 
103.  Togashi Y, Masago K, Masuda S et al. Cerebrospinal fluid concentration of 
gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. 
Pharmacol. 2012; 70(3):399–405. 
104.  Le Rhun E, Taillibert S, Chamberlain MC. Current Management of Adult 
Diffuse Infiltrative Low Grade Gliomas. Curr. Neurol. Neurosci. Rep. 2016; 16(2):15. 
105.  Solomon BJ, Cappuzzo F, Felip E et al. Intracranial Efficacy of Crizotinib 
Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung 
Cancer: Results From PROFILE 1014. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 
2016; 34(24):2858–2865. 
106.  Zhang I, Zaorsky NG, Palmer JD et al. Targeting brain metastases in ALK-
rearranged non-small-cell lung cancer. Lancet Oncol. 2015; 16(13):e510-521. 
107.  Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in 
Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 
373(2):123–135. 
108.  Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in 
Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015; 
373(17):1627–1639. 
109.  Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for 
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-
010): a randomised controlled trial. Lancet Lond. Engl. 2016; 387(10027):1540–1550. 
110.  Barlesi F, Keunchil P, Ciardiello F et al. Primary analysis from OAK, a 
 28 
randomized phase III study comparing atezolizumab with docetaxel in advanced 
NSCLC, ESMO 2016 Congress in Copenhagen (Abstract LBA44_PR)  
111.  Goldberg SB, Gettinger SN, Mahajan A et al. Pembrolizumab for patients with 
melanoma or non-small-cell lung cancer and untreated brain metastases: early 
analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 
17(7):976–983. 
112.  Margolin K, Ernstoff MS, Hamid O et al. Ipilimumab in patients with melanoma 
and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5):459–
465. 
113.  Konstantinou M-P, Dutriaux C, Gaudy-Marqueste C et al. Ipilimumab in 
melanoma patients with brain metastasis: a retro-spective multicentre evaluation of 
thirty-eight patients. Acta Derm. Venereol. 2014; 94(1):45–49. 
114.  Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and 
therapeutic options. Melanoma Res. 2012; 22(3):177–183. 
115.  Dummer R, Goldinger SM, Turtschi CP et al. Vemurafenib in patients with 
BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final 
results of an open-label pilot study. Eur. J. Cancer Oxf. Engl. 1990 2014; 50(3):611–
621. 
116.  Fennira F, Pagès C, Schneider P et al. Vemurafenib in the French temporary 
authorization for use metastatic melanoma cohort: a single-centre trial. Melanoma 
Res. 2014; 24(1):75–82. 
117.  Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or 
Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a 
multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13(11):1087–1095. 
118.  Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or 
what is the role of intra-CSF-chemotherapy? J. Neurooncol. 1998; 38(2–3):151–157. 
119.  Lassman AB, Abrey LE, Shah GD et al. Systemic high-dose intravenous 
methotrexate for central nervous system metastases. J. Neurooncol. 2006; 
78(3):255–260. 
120.  Chahal J, Stopeck A, Clarke K et al. Intravenous thiotepa for treatment of 
breast cancer-related leptomeningeal carcinomatosis: case series. Neurol. Sci. Off. J. 
Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2015; 36(9):1691–1693. 
121.  Benjamin JC, Moss T, Moseley RP et al. Cerebral distribution of 
immunoconjugate after treatment for neoplastic meningitis using an intrathecal 
radiolabeled monoclonal antibody. Neurosurgery 1989; 25(2):253–258. 
122.  Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of 
intrathecally administered cytarabine and methotrexate: a quantitative 
autoradiographic study. J. Natl. Cancer Inst. 1988; 80(15):1211–1216. 
123.  Blaney SM, Cole DE, Godwin K et al. Intrathecal administration of topotecan in 
nonhuman primates. Cancer Chemother. Pharmacol. 1995; 36(2):121–124. 
124.  Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of 
intracerebrospinal fluid chemotherapy administration and efficacy of therapy in 
neoplastic meningitis. Cancer 2010; 116(8):1947–1952. 
125.  Shapiro WR, Schmid M, Glantz M, Miller JJ. A randomized phase III/IV study 
to determine benefit and safety of cytarabine liposome injection for treatment of 
neoplastic meningitis. ASCO Meet. Abstr. 2006; 24(18_suppl):1528.  
126.  Zairi F, Le Rhun E, Bertrand N et al. Complications related to the use of an 
intraventricular access device for the treatment of leptomeningeal metastases from 
solid tumor: a single centre experience in 112 patients. J. Neurooncol. 2015; 
124(2):317–323. 
127.  Kennedy BC, Brown LT, Komotar RJ, McKhann GM. Stereotactic catheter 
 29 
placement for Ommaya reservoirs. J. Clin. Neurosci. Off. J. Neurosurg. Soc. 
Australas. 2016; 27:44–47. 
128.  Morgenstern PF, Connors S, Reiner AS, Greenfield JP. Image Guidance for 
Placement of Ommaya Reservoirs: Comparison of Fluoroscopy and Frameless 
Stereotactic Navigation in 145 Patients. World Neurosurg. 2016; 93:154–158. 
129.  Gwak H-S, Joo J, Shin S-H et al. Ventriculolumbar perfusion chemotherapy 
with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study. The 
Oncologist 2014; 19(10):1044–1045. 
130.  Grossman SA, Finkelstein DM, Ruckdeschel JC et al. Randomized 
prospective comparison of intraventricular methotrexate and thiotepa in patients with 
previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. 
Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1993; 11(3):561–569. 
131.  Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial 
comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal 
methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer 
Res. Off. J. Am. Assoc. Cancer Res. 1999; 5(11):3394–3402. 
132.  Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of 
single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. 
Oncol. Off. J. Am. Soc. Clin. Oncol. 1987; 5(10):1655–1662. 
133.  Cole BF, Glantz MJ, Jaeckle KA et al. Quality-of-life-adjusted survival 
comparison of sustained-release cytosine arabinoside versus intrathecal 
methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003; 
97(12):3053–3060. 
134.  Zagouri F, Sergentanis TN, Bartsch R et al. Intrathecal administration of 
trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive 
metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer 
Res. Treat. 2013; 139(1):13–22. 
135.  Chamberlain MC, Kormanik PA. Prognostic significance of 111indium-DTPA 
CSF flow studies in leptomeningeal metastases. Neurology 1996; 46(6):1674–1677. 
136.  Chamberlain MC. Radioisotope CSF flow studies in leptomeningeal 
metastases. J. Neurooncol. 1998; 38(2–3):135–140. 
137.  Pan Z, Yang G, He H et al. Concurrent radiotherapy and intrathecal 
methotrexate for treating leptomeningeal metastasis from solid tumors with adverse 
prognostic factors: A prospective and single-arm study. Int. J. Cancer 2016; 
139(8):1864–1872. 
138.  Chamberlain MC, Johnston SK. Neoplastic meningitis: survival as a function of 
cerebrospinal fluid cytology. Cancer 2009; 115(9):1941–1946. 
139.  Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to 
do about it? Lancet Oncol. 2012; 13(9):e375-382. 
140.  Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs 
for preventing seizures in people with brain tumors. Cochrane Database Syst. Rev. 
2008; (2):CD004424. 
141.  Jung T-Y, Chung W-K, Oh I-J. The prognostic significance of surgically treated 
hydrocephalus in leptomeningeal metastases. Clin. Neurol. Neurosurg. 2014; 
119:80–83. 
142.  Nigim F, Critchlow JF, Kasper EM. Role of ventriculoperitoneal shunting in 
patients with neoplasms of the central nervous system: An analysis of 59 cases. Mol. 
Clin. Oncol. 2015; 3(6):1381–1386. 
143.  Zhang X-H, Wang X-G, Piao Y-Z et al. Lumboperitoneal shunt for the 
treatment of leptomeningeal metastasis. Med. Hypotheses 2015; 84(5):506–508. 
144.  Yamashiro S, Hitoshi Y, Tajiri S et al. Palliative lumboperitoneal shunt for 
 30 
leptomeningeal metastasis-related hydrocephalus: A case series. Palliat. Med. 2017; 
31(1):93–96. 
145.  Pace A, Linda Dirven L, Koekkoek JAF et al, on behalf of the European 
Association of Neuro-Oncology palliative care task force. EANO guidelines for 
palliative care in adult glioma patients; Lancet Oncol (In Press). 
146.  Brainin M, Barnes M, Baron J-C et al. Guidance for the preparation of 
neurological management guidelines by EFNS scientific task forces--revised 
recommendations 2004. Eur. J. Neurol. 2004; 11(9):577–581. 
147.  Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious 
Diseases Society of America, American Society of Blood and Marrow 
Transplantation. Summary of the Guidelines for Preventing Opportunistic Infections 
among Hematopoietic Stem Cell Transplant Recipients. Clin. Infect. Dis. Off. Publ. 
Infect. Dis. Soc. Am. 2001; 33(2):139–144. 
 
  
 31 
 
Figure 1. Therapeutic approach to LM.  
 
 
 
CSF, cerebrospinal fluid; LM, leptomeningeal metastases.  
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Figure 2. Therapeutic approach to type I LM.  
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This decision tree is based on expert agreement. When selecting therapeutic options, systemic pharmacotherapy should always be 
considered. A modification of systemic pharmacotherapy is recommended in patients with progressive extracranial disease as well as 
in patients with progressive BM, unless RT alone is a preferred option. Intra-CSF pharmacotherapy is recommended in case of floating 
tumour cell load in the CSF and is optional in case of linear metastatic meningeal disease. Intra-CSF therapy is not recommended in 
patients with symptomatic hydrocephalus who require ventriculoperitoneal shunt placement or with a ventricular device without on/off 
option or in patients with nodular meningeal metastases only. Focal radiotherapy is recommended for the treatment of nodular disease 
and symptomatic metastatic cerebral or spinal sites. WBRT may be an option for extensive nodular or symptomatic linear LM or co-
existing BM.  
Note that radiotherapy options refer to treatment for LM only.  
BM, brain metastases; CSF, cerebrospinal fluid; ECD, extracranial disease; IT, intrathecal; LM, leptomeningeal metastases; RT, 
radiotherapy; WBRT, whole brain radiotherapy.  
+: recommended, (+): optional, -: not recommended 
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Figure 3. Therapeutic approach to type II LM. 
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This decision tree is based on expert agreement. When selecting therapeutic options, systemic pharmacotherapy should always be 
considered. A modification of systemic pharmacotherapy is recommended in patients with progressive extracranial disease as well as 
in patients with progressive BM, unless RT alone is a preferred option. Intra-CSF pharmacotherapy is recommended in case of floating 
tumour cell load in the CSF and is optional in case of linear metastatic meningeal disease. Intra-CSF therapy is not recommended in 
patients with symptomatic hydrocephalus who require ventriculoperitoneal shunt placement or with a ventricular device without on/off 
option or in patients with nodular meningeal metastases only. Focal radiotherapy is recommended for the treatment of nodular disease 
and symptomatic metastatic cerebral or spinal sites. WBRT may be an option for extensive nodular or symptomatic linear LM or co-
existing BM. No pathway for type II D was provided because these patients will only exceptionally be treated. 
Note that radiotherapy options refer to treatment for LM only.  
BM, brain metastases; CSF, cerebrospinal fluid; ECD, extracranial disease; IT, intrathecal; LM, leptomeningeal metastases; RT, 
radiotherapy; WBRT, whole brain radiotherapy.  
+: recommended, (+): optional, -: not recommended 
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Table 1. Evaluation of suspected LM 
 
 Recommended protocols of evaluation Results 
Clinical evaluation Standardised neurological evaluation [1] Presence of typical clinical signs of LMa 
Any other neurological abnormality  
Normal neurological evaluation 
Neuroimaging Brain: axial, coronal and sagittal T1 without and with 
contrast enhancement, axial T2, axial and coronal FLAIR 
Spinal axis: sagittal T2 and T1 without and with contrast 
 
Gadolinium should be injected 10 min before data 
acquisition at a dose of 0.1 mmol/kg. The slice thickness 
should be 1 mm or less. 
Typical MRI findings of linear LM (type A)b 
Typical MRI findings of nodular leptomeningeal disease (type B) 
Both (type C) 
Equivocal leptomeningeal MRI findings (type D) 
Absence of leptomeningeal MRI findings (type D) 
CSF cytology - Fresh CSF samples should be processed within 30 
minutes after sampling when feasible; alternatively, 
fresh CSF samples can be fixed with Ethanol-Carbowax 
(CSF/Fixative ratio 1:1)  
- CSF volume is ideally > 10 ml, but at least 5 ml 
- Routine staining for cytological analysis: 
Positive: presence of tumour cells 
Equivocal: suspicious or atypical cells 
Negative: absence of tumour cells 
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Pap/Papanicolaou and (in freshly processed CSF samples) 
Giemsa 
- Additional immunocytochemical staining (upon 
indication and availability of material) for epithelial and 
melanocytic markers; in case of haematological 
malignancy in the differential diagnosis, consider 
immunostainings for lymphoid cells and/or flow 
cytometry analysis of the CSF sample 
- A second CSF sample should be analysed if the initial 
CSF sample is negative 
 
a Typical clinical signs of LM include headache, nausea and vomiting, mental changes, gait difficulties, cranial nerve palsies with 
diplopia, visual disturbances, hearing loss, sensorimotor deficits of extremities and cauda equine syndrome, and radicular neck and 
back pain 
b See Table 2 and text 
CSF, cerebrospinal fluid; FLAIR, fluid-attenuated inversion recovery; LM, Leptomeningeal metastasis; MRI, magnetic resonance 
imaging. 
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Table 2. Diagnostic criteria for LM 
 
  Cytology/ 
biopsy 
 
MRI 
 
Confirmed 
 
Probable* 
 
Possible* 
Lack of 
evidence 
Type I: 
positive CSF 
cytology or 
biopsy 
IA + Linear + n.a. n.a. n.a. 
IB + Nodular + n.a. n.a. n.a. 
IC + Linear + nodular + n.a. n.a. n.a. 
ID + Normal + n.a. n.a. n.a. 
Type II: 
clinical 
findings and 
neuroimaging 
only 
IIA - 
 or 
equivocal 
Linear n.a. With typical 
clinical signs 
Without typical 
clinical signs 
n.a. 
IIB -  
or 
equivocal 
Nodular n.a. With typical 
clinical signs  
 
Without typical 
clinical signs 
 
n.a. 
IIC -  
or 
equivocal 
Linear + nodular n.a. With typical 
clinical signs 
Without typical 
clinical signs 
n.a. 
IID -  
or 
equivocal 
Normal n.a. n.a. With typical 
clinical signs 
Without typical 
clinical signs 
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* Requires a history of cancer 
CSF, cerebrospinal fluid; LM, Leptomeningeal metastasis; MRI, magnetic resonance imaging; n.a., not applicable. 
Type A: LM with typical linear MRI abnormalities; Type B: LM with nodular disease only as type B; Type C: LM with both linear and 
nodular disease; Type D: LM without MRI abnormalities  
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Table 3. Characteristics and schedules of administration of intra-CSF therapy 
 
Agent Description Half-life in the 
CSF 
Recommended schedules of administration Prophylaxis of adverse 
events 
Methotrexate Folate anti-metabolite, cell 
cycle specific drugs 
 
4.5-8 hours 10-15 mg twice weekly (total, 4 weeks), 
then 10-15 mg once weekly (total, 4 weeks) 
then 10-15 mg once monthly 
Folinic acid rescue, 25 mg x 
6 h for 24 h starting 6 h 
after administration 
 
Cytarabine Pyrimidine nucleoside 
analogue, cell cycle specific 
 
<1 hour 10 mg twice weekly (total, 4 weeks) 
then 10 mg once weekly (total, 4 weeks) 
then 10 mg once a month 
None 
Liposomal 
cytarabine 
Pyrimidine nucleoside 
analogue, cell cycle specific 
14-21 days 50 mg every 2 weeks (total, 8 weeks) 
then 50 mg once a month 
Oral steroids, e.g., 6 mg 
dexamethasone equivalent 
daily, (d-1 to d4) 
ThioTEPA Alkylating ethyleneimine 
compound, cell cycle non-
specific drugs 
3-4 hours 10 mg twice weekly (total, 4 weeks) 
then 10 mg once weekly (total, 4 weeks) 
then 10 mg once a month 
None 
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CSF, cerebrospinal fluid 
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Table 4. Key recommendations for the diagnosis and treatment of LM from solid tumours 
 
Diagnosis EANO [146]  ESMO [147] 
 
 Level of evidence Grade of 
recommendation 
 Level of evidence Grade of 
recommendation 
Typical clinical signs of LM such as headache, nausea and vomiting, 
mental changes, gait difficulties, cranial nerve palsies with diplopia, 
visual disturbances, hearing loss, sensorimotor deficits of extremities 
and cauda equine syndrome, radicular, neck and back pain, notably in 
a patient with cancer, should alert clinicians to consider LM 
IV 
III 
n.a. 
C 
 V n.a. 
LM should be considered in particular in patients with breast or lung 
cancer or melanoma who present with neurological symptoms or 
signs. 
III C  III B 
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A detailed neurological examination using a standard evaluation form, 
e.g., as proposed by the LANO group, should be carried out at 
diagnosis  
IV n.a.  V n.a. 
The diagnostic work-up should include cerebrospinal MRI. Brain MRI 
should include axial T1-weighted, axial FLAIR, axial diffusion, axial T2, 
post-gadolinium 3D T1 and post-gadolinium 3D FLAIR sequences. 
Spinal MRI should include post-gadolinium sagittal T1 sequences. 
Spine sagittal T1W sequences without contrast and sagittal fat 
suppression T2-weighted sequences, combined with axial T1W images 
with contrast of regions of interest, may also be considered. 
III C  II B 
CSF flow studies should be considered for patients in whom CSF flow 
obstruction may be present, e.g. hydrocephalus, large nodules 
potentially reducing the CSF circulation on MRI, unexpected toxicity of 
intra-CSF treatment, and who are candidates for intra-CSF 
pharmacotherapy. 
IV 
 
n.a. 
 
 IV C 
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CSF studies with optimised analysis conditions must be carried out as 
part of the diagnostic work-up. One repeat lumbar puncture with 
optimised analysis conditions should be carried out in patients with 
suspected LM and initial negative or equivocal CSF studies. 
IV n.a.  V n.a. 
      
Therapy      
Systemic pharmacotherapy based on primary tumour and previous 
treatment should be considered for most patients with type B/C LM. 
IV n.a.  V n.a. 
Intra-CSF pharmacotherapy should be considered for most patients 
with type IA/C LM. 
IV n.a.  V n.a. 
Intra-CSF chemotherapy should be administered via the ventricular 
rather than lumbar route whenever feasible. 
IV n.a.  V n.a. 
Focal radiotherapy should be considered for circumscribed, notably IV n.a.  V n.a. 
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symptomatic lesions. 
WBRT can be considered for extensive nodular or symptomatic linear 
LM 
IV n.a.  V n.a. 
      
Follow-up      
A detailed neurological examination using a standard evaluation form 
should be carried out every 2-3 months or at radiological progression 
or when new neurological symptoms or signs are reported 
IV n.a.  V n.a. 
Cerebrospinal MRI should be carried out every 2-3 months or at any 
instance of suspected clinical progression. 
IV n.a.  V n.a. 
CSF studies should be carried out every 2-3 months in patients 
undergoing intra-CSF pharmacotherapy. 
IV n.a.  V n.a. 
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Level of evidence and grade of recommendation according to Brainin (EANO recommendations) or Dykewicz (ESMO 
recommendations) [146, 147]  
CSF, cerebrospinal fluid; EANO, European Association of Neuro-Oncology; ESMO, European Society for Medical Oncology; FLAIR, 
fluid-attenuated inversion recovery; LANO, Leptomeningeal Assessment in Neuro-Oncology; LM, Leptomeningeal metastasis; MRI, 
magnetic resonance imaging; n.a., not applicable; WBRT, whole brain radiotherapy 
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Table 5. EANO-ESMO response assessment in LMa 
 
Clinical Imaging CSF  Response determination Action 
Improved or 
stable 
Improved  Improved 
or stable  
Response Continue treatment 
Stable Stable Stable Stable Continue treatment 
Worse Improved or 
stable 
Improved 
or stable 
Suspicion of progression Consider alternative neurological diagnoses or other 
reasons for clinical deterioration,  
change treatment only if there is no other explanation and 
if there is significant worsening of clinical signs for more 
than 2 weeks 
Improved or 
stable 
Improved or 
stable 
Worse Suspicion of progression, or 
progression in case of de novo 
appearance of tumour cells in the 
CSFb 
Continue treatment, change treatment if appearance of 
tumour cells is confirmed on 2 consecutive CSF studies 
from the same CSF site (lumbar or ventricular) at least 4 
weeks apart  
Worse Improved or 
stable 
Worse Suspicion of progression, or 
progression in case of de novo 
appearance of tumour cells in the 
CSFb 
Consider alternative neurological diagnoses, continue 
treatment;   
Change treatment if there is worsening of clinical signs for 
more than 2 weeks and if appearance of tumour cells is 
confirmed on 2 consecutive CSF studies from the same CSF 
site (lumbar or ventricular) at least 4 weeks apart 
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Improved or 
stable 
Worse Improved 
or stable 
Progression Change treatment 
Improved or 
stable 
Worse Worse Progression Change treatment 
Worse Worse Improved 
or stable or 
worse 
Progression Change treatment 
 
a Differences from the LANO recommendations are illustrated in Supplementary Table 2 
b De novo detection of tumour cells as an indicator of progressive disease requires that there were at least 2 adequately performed 
negative CSF analyses 
CSF, cerebrospinal fluid; EANO, European Association of Neuro-Oncology; ESMO, European Society for Medical Oncology; LANO, 
Leptomeningeal Assessment in Neuro-Oncology; LM, Leptomeningeal metastasis 
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Table 6. Levels of evidence and grades of recommendation for a therapeutic intervention (using the European Federation 
of Neurological Societies criteria as recommended by EANO) [146] 
 
 
 
 
 
 
 
 
Reprinted from [146] by permission of European Journal of Neurology. Copyright © 2004, John Wiley and Sons.  
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Table 7. Levels of evidence and grades of recommendation for a diagnostic measure (using the European Federation of 
Neurological Societies criteria as recommended by EANO) [146] 
 
 
 
 
 
Reprinted from [146] by permission of European Journal of Neurology. Copyright © 2004, John Wiley and Sons.  
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Table 8. Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-
United States Public Health Service Grading Systema) 
 
Levels of evidence 
 
I Evidence from at least one large randomised, controlled trial of good 
methodological quality (low potential for bias) or meta-analyses of well-
conducted randomised trials without heterogeneity 
II Small randomised trials or large randomised trials with a suspicion of bias 
(lower methodological quality) or meta-analyses of such trials or of trials 
demonstrated heterogeneity 
III Prospective cohort studies 
IV 
 
Retrospective cohort studies or case–control studies  
 
V Studies without control group, case reports, expert opinions 
 
Grades of recommendation 
 
A Strong evidence for efficacy with a substantial clinical benefit, strongly 
recommended 
B Strong or moderate evidence for efficacy but with a limited clinical benefit, 
generally recommended 
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the 
disadvantages (adverse events, costs, ...), optional  
D              Moderate evidence against efficacy or for adverse outcome, generally not 
recommended 
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E              Strong evidence against efficacy or for adverse outcome, never recommended 
 
a By permission of the Infectious Diseases Society of America (147). 
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Supplementary Table 1. Randomised trials in LM patients from solid tumours* 
Trial Design Population Primary endpoint Efficacy Safety 
Grossman 1993 
[130] 
IT MTX versus 
IT thioTEPA 
Solid tumours 
(n=40),  
CUP (n=1) and 
lymphomas (n=10) 
Neurological 
response rate 
IT MTX vs. IT thioTEPA 
Neurological response rate: none 
Neurological stabilisation: 32% vs. 12.5% 
Survival: 15.9 weeks vs. 14.1 weeks 
IT MTX vs. IT thioTEPA 
Serious toxicities similar in both group 
Mucositis (p=0.04) and neurological complications 
(p=0.008) more frequent in MTX arm 
Hitchins 1997 
[132] 
IT MTX versus 
IT MTX + 
cytarabine 
Solid tumours (n= 
30), cancers of 
unknown primaries 
(n=7) and 
lymphomas (n=7) 
Response rate IT MTX vs. MTX + cytarabine 
Response rate: 61 vs. 45% (p<0.05) 
Median survival: 12 vs. 7 weeks (p<0.05) 
IT MTX vs. MTX + cytarabine  
Nausea and vomiting: 36% vs. 50% 
Septicaemia, neutropaenia: 9% vs. 15% 
Mucositis: 14% vs. 10% 
Pancytopaenia: 9% vs. 10% 
Glantz 1999 
[131] 
IT liposomal 
cytarabine 
versus IT MTX 
Solid tumours 
(n=61) 
Response rate at the 
end of the induction 
period 
IT liposomal cytarabine vs. IT MTX 
Responses rate: 26% vs. 20% (p=0.76) 
Median survival: 105 days vs. 78 days (p=0.15) 
Time to neurological progression: 58 vs. 30 days (p=0.007)  
Neoplastic meningitis-specific survival: 343 vs. 98 days (p=0.074) 
IT liposomal cytarabine vs. IT MTX 
Sensory/motor dysfunction: 4% vs. 10% (p=0.021) 
Visual impairment 0% vs. 13% (p=0.066) 
Chemical meningitis of any grade: 23% vs. 19% (p=0.57) 
Boogerd 2004 
[75] 
IT MTX versus 
no IT 
Breast cancers 
(n=35) 
Overall survival: time 
from randomisation 
until death 
 
IT MTX vs. no IT 
Overall survival:18.3 weeks vs. 30.3 weeks (p=0.32) 
Neurological improvement or stabilisation: 59% vs. 67% (p=NR) 
Median time to progression of 23 weeks and 24 weeks (p=NR) 
IT MTX vs. no IT 
Neurological complications: 47% vs 6% (p=0.0072) 
Shapiro 2006 
[125] 
Solid tumours: 
IT liposomal 
cytarabine 
versus IT MTX 
(lymphomas: 
IT liposomal 
cytarabine 
versus IT 
aracytine) 
Solid tumours 
(n=103) and 
lymphomas (n=25) 
Progression free 
survival: randomised 
to neurological 
progression or death 
IT liposomal cytarabine versus IT MTX or cytarabine 
Median progression free survival: 35 vs. 43 days (p=0.7321) 
 
IT liposomal cytarabine versus IT control  
Drug related AEs: 48% vs. 60% of the serious AEs: 86 vs. 
77% 
 
 2 
AE, adverse event; CUP, cancer of unknown primary; IT, intrathecal; IT MTX, intrathecal methotrexate; LM, Leptomeningeal 
metastasis. 
 
*Note that all randomised trials explored the role of IT chemotherapy and that systemic therapy was commonly allowed, but not 
controlled for. 
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Supplementary Table 2. LANO response criteriaa 
 
 RANO criteria EANO-ESMO criteria 
Response Neurological examination improved, CSF cytology 
negative, neuroimaging with definitive improvement, 
symptom assessment improved 
Clinically improved or stable, neuroimaging improved, CSF 
cytology improved or stable 
Stable Neurological examination stable, CSF cytology negative 
or positive, neuroimaging stable or equivocally 
worsening or improved, symptom assessment stable 
Clinically stable, neuroimaging stable, CSF cytology stable 
Suspicion of progression Not determined Clinically worse, neuroimaging stable, CSF cytology stable 
or 
Clinically stable or worse, neuroimaging stable, CSF cytology 
worse (increased tumour cell counts) 
Progression Neurological examination worse, CSF cytology negative, 
neuroimaging stable, symptom assessment worse or 
stable 
or 
Neurological examination stable, CSF cytology positive 
(lack of consensus), neuroimaging stable, symptom 
assessment worse or stable 
Neuroimaging worse 
or 
de novo positive CSF cytology 
 
 4 
or 
Neurological examination stable, CSF cytology negative, 
neuroimaging definite worsening, symptom assessment 
worse or stable 
 
Adapted from [1]  
aFor clinical decision making refer to table 5 
CSF, cerebrospinal fluid; EANO, European Association of Neuro-Oncology; ESMO, European Society for Medical Oncology; LANO, 
Leptomeningeal Assessment in Neuro-Oncology; RANO, Response Assessment in Neuro-Oncology.  
 
 
 
 
Life expectancy < 1 month
Palliative approach
CSF cytology positive
Type I LM
positive CSF or biopsy
Type II LM
clinical findings and neuroimaging only
Life expectancy ≥ 1 month
Active BMNo active BM
CSF cytology negative
(LM confirmed by biopsy)
Type IIA
• IT therapy (+)
• Modification of 
systemic therapy
or WBRT  +
Type IIB
• IT therapy -
• Modification of  
systemic therapy
(+)
• Focal RT +
Type IIC
• IT therapy (+)
• Modification of 
systemic therapy
• WBRT and/or 
Focal RT +
Type IIA
• IT therapy (+)
• Modification of 
systemic therapy
+
• WBRT (+)
Type IIB
• IT therapy -
• Modification of 
systemic therapy
+
• Focal RT +
Type IIC
• IT therapy (+)
• Modification of 
systemic therapy
+
• WBRT and/or 
Focal RT +
Type IIA 
• IT therapy (+)
• Modification of 
systemic therapy
or WBRT or both
+
Type IIB
• IT therapy -
• Modification of 
systemic therapy
+
• Focal RT +
Type IIC
• IT therapy (+)
• Modification of 
systemic therapy
+ 
• WBRT and/or 
Focal RT +
Type IIA 
• IT therapy (+)
• Modification of 
systemic therapy
+
• WBRT (+)
Type IIB
• IT therapy -
• Modification of 
systemic therapy
+
• Focal RT (+)
Type IIC
• IT therapy (+)
• Modification of 
systemic therapy
+
• WBRT and/or 
Focal RT (+)
No active BM
Stable  
ECD
Progressive 
ECD
Type IA
• IT therapy +
• Modification of 
systemic therapy
(+)
• WBRT (+)
Type IB
• IT therapy +
• Modification of 
systemic therapy
(+)
• Focal RT +
Type IC
• IT therapy +
• Modification of 
systemic therapy
(+) 
• Focal RT +, WBRT 
(+)
Type ID
• IT therapy +
• Modification of 
systemic therapy
(+)
• RT-
Type IA
• IT therapy +
• Modification of 
systemic therapy
+
• WBRT (+)
Type IB
• IT therapy +
• Modification of 
systemic therapy
+
• Focal RT (+)
Type IC
• IT therapy +
• Modification of 
systemic therapy
+
• WBRT or SRT (+)
Type ID
• IT therapy +
• Modification of 
systemic therapy
+
• RT -
Type IA
• IT therapy +
• Modification of 
systemic therapy
or WBRT or both
+
Type IB
• IT therapy +
• Modification of 
systemic therapy
+ 
• Focal RT  +
Type IC
• IT therapy +
• Modification of 
systemic therapy
+
• WBRT and/or 
Focal RT +
Type ID
• IT therapy +
• WBRT and/or 
modification of 
systemic therapy
+
Type IA
• IT therapy +
• Modification of
systemic therapy
+
• WBRT (+)
Type IB
• IT therapy +
• Modification of 
systemic therapy
+
• Focal RT (+)
Type IC
• IT therapy +
• Modification of 
systemic therapy
+
• WBRT and/or 
Focal RT (+)
Type ID
• IT therapy +
• Modification of 
systemic therapy
+
• WBRT (+)
Active BM
Stable  
ECD
Progressive 
ECD
Stable  
ECD
Stable  
ECD
Progressive 
ECD
Progressive 
ECD
